Kornitzer Capital Management Inc. KS trimmed its stake in shares of ICON Public Limited (NASDAQ:ICLR - Free Report) by 27.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,052 shares of the medical research company's stock after selling 26,701 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.08% of ICON Public worth $19,839,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of ICLR. Ashton Thomas Private Wealth LLC purchased a new stake in ICON Public during the second quarter valued at about $54,000. ORG Partners LLC acquired a new position in ICON Public in the 2nd quarter worth approximately $59,000. GAMMA Investing LLC grew its position in ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company's stock worth $82,000 after purchasing an additional 87 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in ICON Public by 17.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company's stock valued at $95,000 after purchasing an additional 42 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of ICON Public by 119.6% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company's stock valued at $130,000 after purchasing an additional 226 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the company. TD Cowen lowered their price target on ICON Public from $369.00 to $285.00 and set a "buy" rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. dropped their target price on ICON Public from $375.00 to $280.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Redburn Atlantic initiated coverage on shares of ICON Public in a report on Monday, October 14th. They set a "neutral" rating and a $311.00 price target for the company. Robert W. Baird lowered shares of ICON Public from an "outperform" rating to a "neutral" rating and set a $340.00 price objective on the stock. in a research note on Thursday, October 24th. Finally, Barclays cut their target price on shares of ICON Public from $330.00 to $275.00 and set an "overweight" rating for the company in a research report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ICON Public presently has a consensus rating of "Moderate Buy" and a consensus target price of $304.27.
Check Out Our Latest Stock Analysis on ICON Public
ICON Public Stock Down 3.9 %
ICON Public stock traded down $8.84 during mid-day trading on Thursday, hitting $215.01. 3,032,586 shares of the company's stock were exchanged, compared to its average volume of 674,813. ICON Public Limited has a 1-year low of $214.79 and a 1-year high of $347.72. The stock has a 50 day moving average of $282.07 and a two-hundred day moving average of $306.05. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock has a market cap of $17.74 billion, a P/E ratio of 24.82, a P/E/G ratio of 1.62 and a beta of 1.25.
ICON Public (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts' consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period in the prior year, the company posted $3.10 EPS. The business's revenue was down 1.2% on a year-over-year basis. As a group, analysts anticipate that ICON Public Limited will post 13.43 EPS for the current fiscal year.
About ICON Public
(
Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Articles
Before you consider ICON Public, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON Public wasn't on the list.
While ICON Public currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
